Also trades as: PAR.AX (ASX) · $vol 0M
PBIGF OTC
Paradigm Biopharmaceuticals Limited
1W: -86.8%
1M: -98.9%
3M: -99.1%
YTD: -99.4%
1Y: -99.2%
3Y: -99.8%
5Y: -99.9%
$0.00
-0.00 (-17.65%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$80K
+53.6% ▲
5Y CAGR: +31.2%
Gross Profit
-$82K
-313.5% ▼
Operating Income
-$61M
-166.6% ▼
Net Income
-$56M
-199.7% ▼
EPS (Diluted)
$-0.16
-168.0% ▼
EBITDA
-$61M
-141.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $79K | $0 | $66K | $52K | $80K |
| YoY Growth | +285.5% | -100.0% | +0.0% | -20.8% | +53.6% |
| Cost of Revenue | $144K | $19K | $9K | $72K | $162K |
| Gross Profit | -$65K | $28K | $57K | -$20K | -$82K |
| Gross Margin | -81.4% | — | 86.3% | -38.2% | -102.8% |
| R&D Expenses | $39M | $53M | $58M | $18M | $54M |
| SG&A Expenses | $9M | $7M | $7M | $5M | $7M |
| Operating Expenses | $48M | $60M | $65M | $23M | $61M |
| Operating Income | -$48M | -$60M | -$65M | -$23M | -$61M |
| Operating Margin | -60498.8% | — | -99077.5% | -43910.6% | -76248.1% |
| Interest Expense | $29K | $16K | $14K | $7K | $2M |
| Income Before Tax | -$47M | -$59M | -$59M | -$25M | -$64M |
| Tax Expense | -$8M | -$7M | $0 | -$7M | -$8M |
| Net Income | -$39M | -$52M | -$59M | -$19M | -$56M |
| Net Margin | -49543.1% | — | -89138.3% | -36014.5% | -70283.8% |
| EPS (Diluted) | $-0.16 | $-0.18 | $-0.20 | $-0.06 | $-0.16 |
| EBITDA | -$47M | -$60M | -$65M | -$25M | -$61M |
| Shares Outstanding | 242M | 290M | 293M | 315M | 370M |